Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Project

Perturbation of apolipoprotein E4 (apoE4) activity in AD pathology using single domain antibodies and targeting them to the brain

Outputs and Outcomes

Code

01D06921

Duration

01 November 2021 → 31 October 2025

Funding

Regional and community funding: Special Research Fund

Promotor

Jan Gettemans

Fellow

Laure Vandevelde

Research disciplines

Medical and health sciences
- Neurological and neuromuscular diseases

Keywords

single domain antibody apoE4 Alzheimer's Disease

Project description

The APOE-ε4 allele is the most prominent genetic risk factor for late onset AD. We will use ApoE4 nanobodies to stabilize the non-pathological conformation of ApoE4, and use photoporation as a means of introducing nanobodies in mammalian cells. In addition, we plan to target nanobodies to the brain in collaboration with prof. Breakefield (Dept. Neurology, Harvard Medical School, Boston).

English

Dutch

English

Cookie settings

In addition to functional cookies which are necessary for the website to function, Ghent University uses non-functional cookies such as statistical cookies and social media cookies. These non-functional cookies can also be placed by third parties, for example to measure the use of the site or to share content on social media. Certain media are only available if you accept the cookies. You can set and modify your cookie preferences yourself. Find out what cookies we use and why in the Cookie Statement.

Analytics

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Powered by